Rehabilitation program for heart inflammation from immunotherapy
Part of Heart & circulation clinical trials.
This study tests a rehabilitation program called ICIAM for people whose heart muscle became inflamed (myocarditis) after immunotherapy for cancer. It combines Western rehab with Traditional Chinese Medicine to help you recover better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- Your cancer was confirmed by a biopsy or cell test.
- You were diagnosed with heart muscle inflammation (myocarditis) caused by immunotherapy.
- Your care team has checked that you've recovered enough to start rehabilitation.
- You meet the Traditional Chinese Medicine pattern of weak energy with phlegm and blood stasis.
- You are able to take care of yourself and expected to live more than 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people who had a heart-related side effect from immunotherapy and are now ready for rehab. It aims to better understand recovery and guide treatment.
This study looks at genetic factors that may affect the risk of heart inflammation (myocarditis) caused by immune checkpoint inhibitors (ICIs), a type of cancer immunotherapy. It aims to find out if your genes make you more likely to develop this side effect.
This research tracks outcomes for cancer patients who developed heart inflammation (myocarditis) while receiving immune checkpoint inhibitor therapy. By studying survival patterns, researchers hope to better understand how to manage this serious side effect and improve care for future patients.
This study looks for specific markers in the blood that can help doctors better understand and treat heart inflammation (myocarditis) caused by immunotherapy in people with lung cancer. If you join, you will help find ways to improve care for other patients.
This study uses heart MRIs to monitor women with gynecologic cancers who are about to start immunotherapy. The goal is to detect early signs of heart problems so doctors can take action quickly.
This trial tests if the drug tofacitinib can help people whose heart inflammation from cancer immunotherapy (called ICI-related myocarditis) does not improve with steroids. If you have this condition, this study may offer a new treatment option.
Hear when a new Immune Checkpoint Inhibitors Related Myocarditis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.